Business Context and Reporting Period
Company: Protalix Biotherapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 12, 2013
Event: Regulation FD Disclosure regarding an upcoming analyst event.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document serves solely to announce a corporate event.
Material Changes
No material financial changes or operational updates were reported in this filing. The primary disclosure is the scheduling of a future presentation.
Guidance, Outlook, and Management Commentary
- Analyst Event: The Company will host an analyst event on Thursday, June 20, 2013, at 8:00 AM EDT in New York City.
- Agenda: Presentations will cover ELELYSO, PRX-102 (for Fabry disease), Oral GCD (for Gaucher disease), and previously undisclosed product candidates.
- Access: The event will be webcast live and archived for 30 days on the Company's website (www.protalix.com).
- Legal Status: The information in Item 7.01 and Exhibit 99.1 is not deemed "filed" under the Exchange Act and is not incorporated by reference unless expressly stated.
Investor Verification Checklist
- Verify the date and time of the analyst event (June 20, 2013, 8:00 AM EDT).
- Confirm the availability of the webcast and slide deck on the Company's website post-event.
- Review the press release (Exhibit 99.1) for specific details on the "previously undisclosed product candidates."
- Note that this 8-K does not provide updated financial guidance or results.